Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for Functional Popliteal Artery Entrapment Syndrome
NCT03631966Phase 2Withdrawn
- Sponsor
- Stanford University
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in functional popliteal artery entrapment syndrome (FPAES), sponsored by Stanford University. Primary endpoints: Visual Analog Scale at 12 weeks and Lower Extremity Functional Scale at 12 weeks. Planned start Oct 2019; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
functional popliteal artery entrapment syndrome (FPAES)
Beyond the preview
Go deeper on NCT03631966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631966.